Repertoire Immune Medicines expanded its Big‑Pharma partnerships by signing an alliance with Eli Lilly to develop tolerizing therapies for autoimmune diseases. Financial terms reported include an $85 million up‑front payment and potential development and commercial milestone payments totaling roughly $1.84 billion, plus tiered royalties—part of a growing slate of industry collaborations validating Repertoire’s Decode immune‑profiling platform. Repertoire has already partnered with Bristol Myers Squibb and Genentech and said the Lilly agreement represents further external validation of its single‑cell immune‑mapping technology. Company leadership framed the deal as confirmation that multiple large pharmaceutical firms see value in Repertoire’s approach to identifying and engineering tolerogenic interventions for chronic immune disorders.